Tehrani Ali 4
4 · Zymeworks Inc. · Filed Jul 13, 2021
Insider Transaction Report
Form 4
Zymeworks Inc.ZYME
Tehrani Ali
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-07-12−12,669→ 44,991 totalExercise: $4.31From: 2013-01-01Exp: 2022-01-01→ Common Shares (12,669 underlying) - Sale
Common Shares
2021-07-12$36.12/sh−12,669$457,635→ 260,325 total - Exercise/Conversion
Common Shares
2021-07-12$4.31/sh+12,669$54,555→ 272,994 total
Holdings
- 55,511(indirect: By Spouse)
Common Shares
Footnotes (4)
- [F1]Pursuant to a 10b5-1 plan entered into May 13, 2021.
- [F2]The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.3062 using the Bank of Canada exchange rate for July 12, 2021 (CAD1.00 = $0.8019).
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.0649 to $36.5902, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 12, 2021 at each separate price.
- [F4]Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of January 1, 2012 and (ii) remainder of underlying shares in 36 equal monthly installments on the last day of month following first anniversary of grant date.